Whitehawk Therapeutics vs X4 Pharmaceuticals
Whitehawk Therapeutics reported revenue of $7 million in fiscal 2025, about the same as X4 Pharmaceuticals' $6 million in fiscal 2025. Whitehawk Therapeutics' revenue fell 72.5% in its latest year, and X4 Pharmaceuticals' grew 150.0%. Whitehawk Therapeutics had an operating margin of -1601.1%, against -1336.7% at X4 Pharmaceuticals. Free cash flow was −$98 million at Whitehawk Therapeutics and −$86 million at X4 Pharmaceuticals.
Side by side
| Whitehawk Therapeutics | X4 Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $7M | $6M |
| Revenue growth | −72.5% | 150.0% |
| Revenue growth a year, last 5 years | −12.7% | 16.7% |
| Gross margin | 89.4% | 11.4% |
| Operating margin | −1,601.1% | −1,336.7% |
| Net margin | −288.3% | −1,218.5% |
| Free cash flow | −$98M | −$86M |
| Free cash flow margin | −1,371.4% | −1,317.2% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 129.0% | 531.0% |
| Last close | $3.12 | $2.96 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $2.6 million | sold $428,889 |
| Piotroski F-score | — | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Whitehawk TherapeuticsX4 Pharmaceuticals
Operating margin
Percent of revenue
Whitehawk TherapeuticsX4 Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Whitehawk TherapeuticsX4 Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Whitehawk Therapeutics and X4 Pharmaceuticals pages.